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ABSTRACT
Introduction: Hot flushes/flashes (HFs) or other
vasomotor symptoms affect between 45 and
97% of women during menopause. Hormone
replacement therapy (HRT) is effective at alle-
viating menopausal symptoms, but some
women cannot or prefer not to take HRT. Since
current non-hormonal options have suboptimal
efficacy/tolerability, there is a pressing need for
an effective, well-tolerated alternative. The
neurokinin 3 receptor (NK3R) has recently been
implicated in the generation of menopausal HFs
and represents a novel therapeutic target to
ameliorate HF symptoms. This review aims to
assess if NK3R antagonists (NK3Ras) are more
effective than Serotonin Norepinephrine Reup-
take Inhibitors (SNRIs)—currently a common
choice for non-hormonal treatment of meno-
pausal HFs.
Methods: Studies were identified after system-
atically searching Ovid MEDLINE and EMBASE
databases based on PRISMA guidelines. Trial
quality and bias were assessed. Key efficacy
outcomes (HF frequency, HF severity and
number of night-time awakenings/night-
sweats) and selected safety outcomes were
extracted and analysed.
Results: Seven SNRI and four NK3Ra placebo-
controlled randomised trials (plus four follow-
up reports) were included in this review. NK3Ra
administration resulted in a larger reduction
from baseline in HF frequency, HF severity and
night-sweats compared to SNRIs. Five of seven
SNRI trials showed a reduction in HF frequency
that was statistically significant (by 48–67%
from baseline at weeks 8 or 12) whereas all
NK3Ra trials showed a statistically significant
reduction in HF frequency (by 62–93% from
baseline at weeks 2, 4 or 12). While SNRI trials
reported poor tolerability, particularly nausea,
NK3Ra trials reported good tolerability overall,
although two trials reported elevation in
transaminases.
Conclusion: NK3Ras trials show encouraging
efficacy and tolerability/safety. Completion of
phase 3 NK3Ra trials are required to confirm
efficacy and uphold safety/tolerability data but
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phase 2 results suggest that NK3Ras are more
effective than SNRIs for non-hormonal treat-
ment of menopausal HFs.
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Between 45 and 97% of menopausal
women suffer vasomotor symptoms (hot
flushes/flashes and night-sweats) which
can significantly impact their quality of
life and 10–20% find them almost
intolerable.
Conventional treatment is hormone
replacement therapy (HRT) but some
women cannot or prefer not to take HRT.
However, current non-hormonal options
have suboptimal efficacy and tolerability.
Neurokinin B, predominantly acting via
the neurokinin 3 receptor (NK3R), has
been implicated in the generation of
menopausal hot flushes/flashes.
We undertook a systematic qualitative
review to compare outcomes of placebo-
controlled randomised clinical trials using
neurokinin 3 receptor antagonists
(NK3Ras) with those using Serotonin
Norepinephrine Reuptake Inhibitors
(SNRIs) for the non-hormonal treatment
of menopausal hot flushes/flashes.
NK3Ra trials reported numerically superior
efficacy and better safety/tolerability
compared with SNRIs trials. Provided that
phase 3 NK3Ra trials are supportive,
NK3Ras appear a promising therapy for
this challenging area.
INTRODUCTION
Hot flushes/flashes (HFs), defined as transient
sensations of heat, flushing, sweating and chills,
affect between 45 and 97% of women during
menopause and can significantly degrade their
quality of life [1]. HFs often lead to sleep dis-
turbances for a prolonged period, with recurrent
episodes occurring over a median duration of
7.4 years [2]. Between 10 and 20% of women
find HFs almost intolerable [3]. While the full
pathophysiological mechanism of HFs remains
elusive, oestrogen deficiency appears to play a
causative role. Hormone replacement therapy
(HRT) remains the most commonly prescribed
treatment to alleviate menopausal symptoms
provided there are no contraindications
(Table 1) [4]. However, the use of HRT has
decreased after reports of increased risk of car-
diovascular (CV) disease, breast cancer, stroke
and pulmonary embolism [5]. While subse-
quent data suggest that the benefits of HRT
typically outweigh the risks for women without
contraindications, many now seek non-hor-
monal alternatives.
Table 1 Typical contraindications for hormone replace-
ment therapy [4]
Contraindications for hormone replacement therapy
Current, past, or suspected breast cancer
Known or suspected oestrogen-dependent cancer
Undiagnosed vaginal bleeding
Untreated endometrial hyperplasia
Previous idiopathic or current venous
thromboembolism (deep vein thrombosis or
pulmonary embolism), unless the woman is already
on anticoagulant treatment
Active or recent arterial thromboembolic disease (for
example, angina or myocardial infarction)




Current non-hormonal treatment options
include Serotonin Norepinephrine Reuptake
Inhibitors (SNRIs) or Selective Serotonin
Reuptake Inhibitors (SSRIs), clonidine, gaba-
pentin and pregabalin. Of these, SNRIs/SSRIs are
probably the most commonly recommended
Fig. 1 Relationship between KNDy neurons, GnRH
neurons, and the heat-defence pathway. KNDy neurones
in the infundibular nucleus secrete the neuropeptides Kiss
(encoded by the KISS1 gene), NKB (encoded by the
TAC3 gene) and Dyn (encoded by the PDYN gene). NKB
and Dyn act autosynaptically, stimulating and inhibiting
further Kiss release, respectively. Kiss acts on GnRH
neurones. GnRH stimulates LH and FSH release from the
anterior pituitary which stimulates ovarian sex steroid
production. During menopause, lack of oestradiol (E2)
negative feedback results in increased expression of KISS1
and TAC3 mRNA but decreased expression of PDYN
mRNA. Consequently, KNDy neurones become hyper-
trophied, as seen by increased size of nuclei/nucleoli and
increased Nissl substance. KNDy neurones project to the
hypothalamic thermoregulatory centre (the median POA
and adjacent MnPO). During menopause, the increase in
NKB signalling and overstimulation of KNDy neurons
increases activity in the thermoregulatory centre which
then becomes hypersensitive to external cues from periph-
eral sensors, leading to activation of heat dissipation
effectors. KNDy kisspeptin–neurokinin B–dynorphin, Kiss
kisspeptin, NKB neurokinin B, Dyn dynorphin, GnRH
gonadotropin-releasing hormone, LH luteinizing hor-
mone, FSH follicle-stimulating hormone, POA pre-optic
area, MnPO median preoptic nucleus, E2 oestradiol, ERa
oestrogen receptor alpha, PR progesterone receptor, KISS1
kisspeptin gene, TAC3 tachykinin 3 gene, PDYN pro-
dynorphin gene. The figure was created
with BioRender.com
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[6], with data for venlafaxine considered the
most convincing [7]. Nevertheless, none of the
current non-hormonal drugs have optimal effi-
cacy and use in clinical practice may be limited
by side effects or by interactions with other
medications (for example, paroxetine or other
CYP2D6 inhibitors should not be co-prescribed
with tamoxifen [7] which is clinically relevant
considering that a key indication for a non-
hormonal treatment is prior breast
cancer). Therefore, there remains a pressing
need for an effective and well-tolerated non-
hormonal alternative.
The hypothalamic neuropeptide kisspeptin
(Kiss; encoded by the KISS1 gene) is required for
human fertility being a potent stimulator of the
hypothalamic–pituitary–gonadal axis (Fig. 1)
[8]. In primates, a population of Kiss neurones
located in the hypothalamic infundibular
nucleus co-express the neuropeptides, neu-
rokinin B (NKB) and dynorphin (Dyn), and are
thus termed kisspeptin–neurokinin B–dynor-
phin (KNDy) neurones [9]. NKB [encoded by the
tachykinin 3 (TAC3) gene] and Dyn [encoded by
the prodynorphin (PDYN) gene] regulate pul-
satile Kiss secretion from KNDy neurones by
acting auto-synaptically via neurokinin 3
receptors (NK3R) and Dyn (kappa opioid)
receptors to stimulate and inhibit the release of
Kiss, respectively [10]. KNDy neurones project
to the hypothalamic thermoregulatory centre in
mammals (the median preoptic area and adja-
cent median preoptic nucleus) [11]. Gonadal
feedback is transmitted by oestrogen receptor
alpha (ERa) and progesterone receptors (PR)
expressed on Kiss neurons. KNDy neurones are
normally stimulated by NK3R activation and
inhibited by oestrogen. However, during
menopause declining oestrogen levels leads to
NKB hypersecretion, and overstimulation of
KNDy neurons in particular. This elicits
increased activity in the thermoregulatory cen-
tre, which shifts the thermoneutral zone
increasing sensitivity to external cues and trig-
gering more frequent heat dissipation responses
such as HFs [12].
Blockade of NKB signalling with the use of
an NK3R antagonist (NK3Ra) is proposed to
normalise KNDy neurone activity and thus may
help alleviate HFs in menopausal women. This
review aimed to (1) evaluate randomised con-
trolled trials (RCTs) reporting the efficacy and
tolerability of NK3Ras for the treatment of
menopausal HFs and (2) to put these findings in
clinical context by qualitative comparison with
outcome data from RCTs using the SNRI ven-
lafaxine (or the succinate salt of its active
metabolite, desvenlafaxine) to treat menopau-
sal HFs.
METHODS
To put the clinical outcomes of the NK3Ra
studies into context, a clinically relevant alter-
native non-hormonal therapy was required for
comparison. While arguments could be made
for selecting any one of the SNRIs/SSRIs, cloni-
dine, gabapentin or pregabalin, multiple
guidelines and reviews suggest that SSRIs/SNRIs
are the most commonly recommended [6], with
trial evidence strongest for venlafaxine/desven-
lafaxine, paroxetine and citalopram/escitalo-
pram [13]. Of these, venlafaxine (or its active
metabolite desvenlafaxine) was selected for 3
reasons: modest current use was confirmed after
consultation with each of 4 UK regional
menopause clinics (London, Edinburgh, Cardiff
and Belfast), a College report considered the
most convincing SSRI/SNRI efficacy data were
for venlafaxine [7], and, since venlafaxine does
not interact with tamoxifen, it is the preferred
treatment for breast cancer survivors taking
tamoxifen [14], a key indication for a non-hor-
monal menopause treatment. In contrast, the
SSRI paroxetine is a potent CYP2D6 inhibitor
and is contra-indicated with tamoxifen. The
SSRI fluoxetine and SNRI duloxetine are also
CYP2D6 inhibitors (albeit more moderate).
A systematic search of the published litera-
ture up to 17/2/2021 was undertaken on Ovid
MEDLINE and EMBASE, based on PRISMA
guidelines [15] and using the following key
words: ‘‘venlafaxine’’, ‘‘desvenlafaxine’’, ‘‘hot
flushes’’, ‘‘hot flashes’’, ‘‘vasomotor symptoms’’,
‘‘VMS’’, ‘‘menopause’’, ‘‘neurokinin B’’, ‘‘dynor-
phin’’, ‘‘kisspeptin’’, ‘‘kappa’’, ‘‘neurokinin 1’’,
‘‘neurokinin 3’’, ‘‘neurokinin B’’. Further studies
were identified by cross-referencing references
from the qualifying studies. Duplicates were
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removed and studies were screened using
inclusion/exclusion criteria.
Inclusion criteria were: studies of peri-
menopausal, menopausal and postmenopausal
women (natural or surgically induced only),
having HFs, receiving NK3Ra or venlafaxine/
desvenlafaxine treatment, comparison with a
placebo arm, frequency and severity of HFs
reported, primary research design and in Eng-
lish language.
Exclusion criteria were: pre-menopausal
women, chemically or medically induced
menopause, not having HFs, not receiving
treatment with NK3Ra or venlafaxine/desven-
lafaxine, or receiving treatment for HFs in
addition to NK3Ra or venlafaxine/desvenlafax-
ine. Qualifying studies were required to meet all
inclusion criteria and studies discarded if they
met any one of the exclusion criteria.
Only women with natural or surgically-in-
duced menopause were included to ensure a
definitive and irreversible diagnosis. Women
with medically-induced menopause (such as
chemotherapy or use of GnRH analogues) were
excluded, as their ovarian function may have
had the potential to recover (and reverse
menopause). Men were excluded due to the
different physiology involved in the develop-
ment of HFs.
Women concurrently receiving any other
medications to relieve HFs other than the study
drugs were excluded so that the measured effect
could be attributed solely to the drugs under
investigation.
A large placebo effect is well described in HF
treatment trials [16], thus only studies compar-
ing the active drug versus placebo were selected
so that the drug’s effect could be evaluated in
context.
Once qualifying studies were identified,
study quality was assessed using Critical
Appraisal Skills Programme (CASP) methodol-
ogy [17]. The CASP method evaluated four main
components (study design, methodology,
reporting of results and clinical implications),
with each component addressed by either 2 or 3
questions. The Cochrane Collaboration’s tool
[18] was used to assess for risk of bias in each
study, comprising 7 questions defined by the
Cochrane handbook to evaluate selection
(randomisation or allocation concealment),
reporting, performance, detection, attrition and
other bias. One author (S.J.M.) undertook the
primary detailed evaluation of quality and bias
for each study. Equivocal findings were dis-
cussed with a second author (J.A.T.) to reach
consensus.
To enable comparison of SNRI and NK3Ra
outcomes, while studies may include different
outcome measures [19], each qualifying study
was assessed for the specific key efficacy out-
comes of HF frequency, HF severity and, if sta-
ted, night-time awakenings due to HFs, plus
safety/tolerability outcomes including common
adverse events (AEs), serious adverse events
(SAE) and discontinuation due to AEs. Since
SNRI studies were phase 3 whereas NK3Ra trials
were phase 2, a systematic qualitative review
rather than a meta-analysis was considered the
most appropriate.
This paper is based on previously published
data and does not involve any new studies with
human or animal subjects performed by any of
the authors.
RESULTS
Figure 2 illustrates the PRISMA flow diagram
summarising the search process. The initial
search yielded 651 records. After 127 duplicates
were removed, 524 studies were screened for
inclusion (based on the inclusion/exclusion
criteria). A total of 500 studies were excluded
based on the title or abstract. The remaining 24
studies required assessment of the full text, and
a further three studies were found by cross-ref-
erencing references from these studies. This
resulted in 15 qualifying studies for qualitative
synthesis (seven SNRI trials plus two follow-up
papers [20–28] and four NK3Ra trials plus two
follow-up papers [29–34]).
Table 2 summarises the CASP quality assess-
ment for each study. For illustrative purposes,
when assessing the four components, if all
answers were ‘Yes’, the score was designated as
‘high’ quality of evidence (green). If one or
more answers was ‘No’, the score was assigned
as ‘low’ quality of evidence (red). If one or more
answers was ‘cannot tell’ (but none was ‘no’)
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the score was assigned as ‘unclear’ quality of
evidence (orange). The full quality analysis for
each study is available upon request. Overall,
the studies were mostly of high quality.
Table 3 summarises the Cochrane Collabo-
ration’s tool bias assessment for each study. For
illustrative purposes, a low risk of bias subtype
was shown as green, a high risk as red and an
unclear risk as orange. The full quality analysis
for each study is available upon request. Over-
all, the studies were mostly of low bias.
Table 4 summarises the study design, efficacy
and tolerability/safety outcomes for SNRI trials.
Overall, the SNRI trials showed modest HF
reduction. There was a statistically significant
Fig. 2 PRISMA flow diagram summarising the search strategy used to identify qualifying studies [15]
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reduction in HF frequency versus placebo in five
of seven trials [21–23, 25, 27] (48–67% reduc-
tion from baseline at week 8 or 12 in the setting
of a 25–51% placebo response) and a statisti-
cally significant reduction in HF severity versus
placebo in five of seven trials [21–23, 25, 27] for
at least one dose and one time point (24–31%
reduction from baseline at week 12 in the set-
ting of a 12–18% placebo response where per-
centage data were reported). Night-time
awakenings due to HFs showed a statistically
significant reduction in the three trials [21–23]
that measured this outcome (53–77% reduction
from baseline at week 12 in the setting of
44–63% placebo response). However, HF fre-
quency and HF severity did not show a statisti-
cally significant reduction versus placebo in two
SNRI trials [20, 24]. SNRI-treated subjects expe-
rienced more AEs (in all trials) and discontinu-
ations due to AEs (in all but one trial [22]) versus
placebo. Common AEs included nausea, dry
mouth, insomnia, dizziness and constipation
(with nausea being reported to be the most
debilitating).
Table 5 summarises the study design efficacy
and tolerability/safety outcomes for NK3Ra
trials.
Table 2 Quality of evidence summary for (A) SNRI and (B) NK3Ra studies, assessed using Critical Appraisal Skills
Programme checklists [17]
(A) SNRI studies (B) NK3Ra studies 
✓ = High quality of evidence 
✗ = Low quality of evidence 







































































































































































Is the basic study design valid for a randomised 
controlled trial?  
Did the study address a clearly focused 
research question? 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Was the assignment of participants to 
interventions randomised? 
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Were all participants who entered the study 
accounted for at its conclusion? 
✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Was the study methodologically sound?  
Were the participants, investigators and 
people assessing/analysing blinded? 
? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Were the study groups similar at the start of 
the randomised controlled trial? 
✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Did each study group receive the same level 
of care?  
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
What are the results?  
Were the effects of intervention reported 
comprehensively? 
✗ ✗ ✗ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ ✓ ✓
Was the precision of the estimate of the 
intervention effect reported?  
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Do the benefits of the intervention outweigh 
the harms and costs?  
? ✓ ✓ ✓ ? ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Will the results help locally?  
Can the results be applied to your local 
population/in your context?  
✓ ? ? ? ? ? ? ✓ ✓ ? ? ? ? ? ? 
Would the intervention provide greater value 
than any existing intervention?  
✗ ✓ ✓ ✓ ? ✓ ✓ ✓ ✓ ? ? ? ? ? ? 
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Overall, in comparison to SNRI trials, the
NK3Ra trials reported a larger reduction versus
baseline in HF outcomes. NK3Ras led to a sta-
tistically significant reduction in HF frequency
versus placebo at all time points, across all four
trials, apart from the two lowest doses in the
dose-ranging study by Trower et al. [34]
(62–93% reduction from baseline at weeks 2, 4
or 12 in the setting of a 28–55% placebo
response). HF severity also showed a reduction
versus placebo in all trials (41–94% reduction
from baseline measured at weeks 2, 4 or 12 in
the setting of a 5–46% placebo response),
although not all doses reached significance at
all time points in the two dose-ranging trials
[32, 34]. The number of night-time HFs/fre-
quency of waking due to night-sweats showed a
statistically significantly reduction versus pla-
cebo in the two trials [30, 34] that measured this
outcome (63–81% reduction from baseline at
weeks 2 and 4 in the setting of a 22–32% pla-
cebo response).
DISCUSSION
In this qualitative analysis, NK3Ras reported
larger reductions from baseline compared to
SNRIs in terms of HF frequency, HF severity and
night-sweats. All four NK3Ra trials reported
statistically significant reductions in HF fre-
quency by 62–93% from baseline at weeks 2, 4
or 12 (in the setting of a 28–55% placebo
response), whereas only five of seven SNRI trials
reported reduced HF frequency by 48–67% from
baseline at weeks 8 or 12 (in the setting of a
25–51% placebo response) and two of seven
trials reported no significant reduction. NK3Ra
trials reported generally good tolerability
(although transaminases elevation was noted in
two trials) whereas SNRI trials reported less
favourable tolerability, with nausea being
common.
Trial Strengths and Weaknesses
While both the SNRI and NKR3a trials had
many strengths, potential limitations were
Table 3 Risk of bias summary for the (A) SNRI and (B) NK3Ra studies, assessed using the Cochrane Collaboration’s tool
[18]
(A) SNRI studies (B) NK3Ra studies
 = Low risk of bias 
 = Unclear risk of bias 
 = High risk of bias 







































































































































































Random sequence generation (selection 
bias)  
Allocation concealment  
(selection bias)  
Selective reporting  
(reporting bias)  
Other sources of bias 
Blinding of participants and personnel 
(performance bias)  
Blinding of outcome assessment 
(detection bias)  
Incomplete outcome data  
(attrition bias)  
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Table 4 Serotonin-norepinephrine reuptake inhibitor (SNRI) study results






12-week RCT: 1 US centre
Mean age = 52.15 years
80 randomised (1:1) to venlafaxine XR (37.5 mg/day for 1
week, titrated to 75 mg/day for 11 weeks) vs. placebo
1:
# of mild, mod, severe,






1: absolute or %; data not reported
No sig. ; in HF # vs. placebo (p = 0.2)
No sig. ; in mean HF severity (p value not given)
2:
AEs: : in dry mouth (81% vs. 44%), : in sleeplessness
(88% vs. 47%) and ; appetite (81% vs. 53%) vs. placebo
: withdrawals [11 vs. 8 (p = ns)] due to difficulty






1 efficacy evaluations completed at 4 and 12 weeks
Safety and tolerability data collected for 52 weeks
52 week DBRCT; dose-ranging trial: 37 US centres
Mean age = 53 years (37–78)
Mean BMI = 26.96 kg/m2
707 randomised (2:2:2:2:1) to desvenlafaxine 50, 100, 150,
or 200 mg/day vs. placebo for 52 weeks
620 included in mITT analysis
1:
D from BL in avg. daily #
of mod/severe HFs at
week 4 and 12
D from BL in avg. daily
HF severity score at
week 4 and 12
2:
D from BL in daily # of
night-time awakenings






; from BL in avg. daily # of mod/severe HFs vs. placebo
(No ; with 50 mg or 200 mg)
100 mg ; at week 4 (- 6.62 vs. - 5.22; p = 0.013) and
week 12 [- 7.23 (64%;) vs. - 5.50 (51%;); p = 0.005]
150 mg ; at week 12 [- 6.94 (60%;) vs. - 5.50 (51%;);
p = 0.020], but not at week 4
; from BL in avg. daily HF severity scores vs. placebo (No ;
with 50 mg or 150 mg)
100 mg ; at week 12 [- 0.80 (31%;) vs. - 0.47 (18%;);
p = 0.002], but not at week 4
200 mg ; at week 12 [- 0.74 (27%;) vs. - 0.47 (18%;);
p = 0.013], but not at week 4
2:
; daily # of night-time awakenings vs. placebo at week 12
(week 4 not reported) (No ; with 50 mg)
100 mg, 150 mg and 200 mg ; at week 12 [- 2.77/night
(76.9%;), p = 0.013; - 2.69/night (69%;), p = 0.034
and - 2.68/night (70.5%;), p = 0.043, respectively vs.
- 2.21/night (63.1%;)]
AEs vs. placebo
150 mg and 200 mg : AEs during week 1 only (both
p\ 0.05), most commonly, nausea, dry mouth, insomnia
(No : with 50 mg and 100 mg)
3 SAEs possibly Tx-related: 2 increased LFTs, 1
cholecystitis
: hypertension (5.9% overall vs. 1.3% placebo; p = ns). 5
vs. 0 CV events at 1 year (p = ns)
: discontinuations due to AEs 150 and 200 mg during











12 week DBRCT: 34 US centres
Mean age = 53.36 years (29–71)
Mean BMI = 27.86 kg/m2 (17.2–40.1)
458 randomised to desvenlafaxine 100 mg/day or
150 mg/day vs. placebo for 12 weeks [50 mg/day for
3 days, titrated to 100 mg/day on day 4 (titrated to
150 mg/day on day 8 for 150 mg/day group)]
2 week dose-tapering
436 included in mITT analysis
1:
D from BL in avg. daily #
mod/severe HFs at
weeks 4 and 12
D from BL in avg. daily
HF severity score at
weeks 4 and 12
2:
D from BL in # of night-
time awakenings at





; daily # of HF from BL vs. placebo with 100 mg and
150 mg at week 4 (both p B 0.012, no % given) and
week 12 (65.4%;, p = 0.005; and 66.6%;, p = 0.012,
respectively vs. 50.8%;)
; daily HF severity score from BL vs. placebo with 100 mg
and 150 mg at week 12 [- 0.65 (27%;); and - 0.66
(27.5%;), respectively vs. - 0.33 (13.75%;); both
p\ 0.001], and at all other time points
2:
; daily # of night-time awakenings from BL vs. placebo
with 100 mg and 150 mg at week 4 (- 1.8 and - 1.6,
respectively vs. - 1.2) and week 12 [- 2.0 (60.6%;) and
- 1.8 (58.1%;), respectively vs. - 1.4 (43.8%;)]; all
p B 0.048
: AEs during week 1 only vs. placebo (84.1% vs. 69.5%;
p = 0.002), most commonly nausea (25.2%), dry mouth,
insomnia, constipation, asthenia
2 SAEs possibly Tx-related: hypertension (1 subject with
150 mg : SBP by 4.52 mmHg at week 12 (p = 0.002),
bronchospasm (1 subject but on placebo)
Discontinuation due to AEs: no diff. [but numerically : in







26 week DBRCT: 32 US centres
Mean age = 53.7 years
Mean BMI = 27.1 kg/m2 (15.9–40.4)
567 randomised to desvenlafaxine 100 mg/day or
150 mg/day vs. placebo for 26 weeks
484 included in mITT analysis
1:
D from BL in avg. daily #
of mod/severe HFs at
weeks 4 and 12
D from BL in avg. daily
HF severity at weeks 4
and 12
2:
D from BL in # of night-






; daily # of HFs from BL vs. placebo at week 4 and 12
(week 12: 100 mg 60%;, p = 0.002; 150 mg 66.6%;,
p\ 0.001, vs. 47%;)
150 mg maintained ; at week 26 (69%; vs. 51%;,
p = 0.001), whereas 100 mg did not (61%;, p = 0.061)
but study not powered for efficacy[ 12 weeks
; daily HF severity from BL vs. placebo at week 4 and 12
(week 12: 100 mg 24%;, p = 0.002; 150 mg 29%;,
p\ 0.001 vs. 13%;). 150 mg maintained ; at week 26
(p = 0.008, no % given)
2:
; daily # of night-time awakenings from BL vs. placebo at
week 4 (actual ; not given) and week 12 [100 mg - 2.0
(52.6%;); 150 mg - 2.4 (68.6%;) vs. - 1.6 (47.1%;)];
all p B 0.026
: AEs during week 1 only vs. placebo (p\ 0.05), most
commonly nausea (44.6%), dizziness, insomnia, dry
mouth, constipation
: SAE possibly Tx-related: hypertension (100 mg)
: discontinuations due to AEs during week 1 only vs.
placebo (16.1% vs. 0.6%; p\ 0.001)
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Table 4 continued





12-week DBRCT: 35 European centres, 2 centres in South
Africa, 1 centre in Mexico
Mean age = 53.6 years (40–66 years)
Mean BMI = 26 kg/m2 (16–34)
C 485 randomised (1:1:1) to desvenlafaxine 100 mg/day,
tibolone 2.5 mg/day, vs. placebo for 12 weeks
451 included in mITT analysis
1:
D from BL in avg. daily #
of mod/severe HFs at
weeks 4 and 12
D from BL in avg. daily







No ; in daily # of HFs from BL vs. placebo at week 4
(- 4.63 vs. - 4.38, p = 0.558) and week 12 (- 5.78
(57.7%;) vs. –5.82 (57.5%;), p = 0.921]
No ; in daily HF severity from BL vs. placebo at week 4
(- 0.37 vs. - 0.31, p = 0.352) and week 12 [- 0.61
(26.8%;) vs. - 0.61 (26.5%;), p = 0.943]
2:
: AEs with desvenlafaxine vs. tibolone and placebo (73.4%
vs. 64.5% and 55.9%, respectively), most commonly
nausea (31%), dizziness and constipation
: bleeding with tibolone vs. desvenlafaxine and placebo
[23% vs. 12% (p = 0.024) and 9% (p = 0.001),
respectively]
: discontinuations due to AEs during week 1 only vs.






52-week DBRCT: 122 US and Canadian centres
Mean age = 54 years (45–71)
Mean BMI = 26.45 kg/m2 (16.9–35.3)
396 randomised (1:1) to desvenlafaxine 100 mg/day vs.
placebo for 52 weeks (50 mg/day for 1 week, titrated to
100 mg/day for 51 weeks)
2 week dose-tapering
365 included in mITT analysis
Pinkerton et al. (2013) [25] reports 12-week data from an
efficacy substudy (part of a larger n = 2186 safety study)
1:
D from BL in avg. daily #
of mod and severe HFs
at weeks 4 and 12
D from BL in avg. daily
HF severity scores at






; daily # of HFs vs. placebo at week 4 [- 6.5 HFs (55%;)
vs. - 3.6 (31%;); p\ 0.001] and week 12 [- 7.3 HFs
(62%;) vs. - 4.5 (38%;); p\ 0.001]
; daily HF severity score vs. placebo at week 4 [- 0.47
(20%;) vs. - 0.19 (8%;); p\ 0.001] and week 12
[- 0.59 (25%;) vs. - 0.28 (12%;); p\ 0.001]
2:
: AEs vs. placebo during week 1 only (p\ 0.001), mostly
nausea, dry mouth, constipation (but no diff. in BP)
2 SAEs: 1 squamous cell carcinoma, 1 multi-event SAE
(altered mental status with slurred speech, uncontrolled
hypertension, resolved hypokalemia, polypharmacy)
: discontinuations due to AEs vs. placebo (10.0% vs. 3.7%;





Pinkerton et al. (2013) [26] reports 52-week data from the
same efficacy substudy population
See above
1:
D from BL in avg. daily #
of HFs at weeks 12, 26,
52
D from BL in avg. daily
HF severity scores at






; in daily # of HFs at 12 weeks [- 7.5 HFs (64%;) vs.
–5.0 (43%;); p\ 0.001], 26 weeks [- 8.6 HFs (74%;)
vs. - 6.3 (54%;); p\ 0.001 and 52 weeks [- 7.7 HFs
(66%;) vs. - 4.8 (41%;); p\ 0.001]
; in daily HF severity score at 12 weeks [- 0.63 (27%;) vs.
- 0.3 (13%;); p\ 0.001], 26 weeks [- 0.85 (36%;) vs.
- 0.53 (22%;); p = 0.001] and 52 weeks [- 0.75
(32%;) vs. - 0.44 (19%;); p = 0.003]
2: includes efficacy substudy (n = 365) and larger safety
population (n = 2186)
: AEs vs. placebo (84% vs. 79%; p = 0.006), most
commonly nausea (21%), headache, dry mouth and
insomnia. Rates of new-onset AEs were similar by week 3
SAEs: No excess CV ischaemic events vs. placebo over 52
weeks
: discontinuations due to AEs vs. placebo (18.3% vs. 9.7%;
p\ 0.001); rates highest during week 1
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observed regarding generalisability and trial
design which are important to note in order to
place overall results in context and to consider
when evaluating differences between treatment
groups.
Age
HF symptoms are typically most severe around
the final menstrual period. While mean age in
the SNRI (53–55 years) and NK3Ra (54–55 years)
trials was similar, the range was much greater in
the SNRI trials (29–78 years vs. 41–65 years).
This is relevant since it is unknown if treatment
is equally effective in all menopause phases.
Ethnicity
Studies have shown ethnicity to affect HF
prevalence with the highest frequency in
Turkish women (97%) and the lowest in South
American (47%) and Asian (45%) women [1].
Most SNRI trials predominately (* 75–80%)
recruited Caucasian women from North Amer-
ican centres which is a limitation since HF fre-
quency can vary by population, often less in
Asians, but greater in African-Americans [35].
NK3Ra trial participants were mainly Caucasian
with few Asians, although an ongoing trial with
fezolinetant is recruiting Asian women
(NCT04234204) and a trial is planned in Chi-
nese women (NCT04793204).
Menopause Definition
It is preferable to exclude perimenopausal
women since symptoms might improve sec-
ondary to fluctuating hormone levels but be
mistakenly attributed to the study drug. The
Table 4 continued






DBRCT: 3 US centres
Mean age = 54.6 years
Mean BMI = 28.3 kg/m2
339 randomised (2:2:3) to venlafaxine XR 75 mg/day
(37.5 mg/day titrated to 75 mg/day over 1 week), oral
17-beta-oestradiol (ET) 0.5 mg/day or placebo for 8
weeks
Venlafaxine followed by 2-week dose-tapering
330 included in mITT analysis
1:
Mean daily # of HFs at
weeks 4 and week 8
2:





; # of HFs from BL vs. placebo at week 4 (48%; vs. 25%;;
p = 0.005) and week 8 (48%; vs. 29%; p = 0.005)
2: baseline or %; data not reported
; HF severity vs. placebo at week 8 (mean diff. vs. placebo:
- 0.2, p = 0.02)
: AEs vs. ET and placebo (69% vs. 56% and 62%,
respectively; p = ns), most commonly fatigue
12 developed SBP[ 165 mmHg or DBP[ 95 mmHg
(10.4% venlafaxine, 2.1% ET, 0 placebo), but all had BL
SBP or DBP[ study population mean. Vaginal bleeding
8.2% ET, 0% venlafaxine, and 1.6% placebo
: discontinuations due to AEs vs. placebo (5 venlafaxine, 4













; (improved) mean total MENQoL score from BL vs.
placebo at week 4 and week 8 (week 8: - 0.9 vs. - 0.7,
p = 0.042)
Only sig. diff. vs. placebo in psychosocial domain (week 8:
- 1.5 vs. - 1.3, p = 0.008)
No improvements vs. placebo with respect to changes in
pain (PEG), depressive symptoms (PHQ-9) or anxiety
(GAD-7) at weeks 4 and 8
; (improved) perceived stress vs. placebo at week 4 and
week 8 (week 8: - 3.4 vs. - 2.0, p = 0.02)
DBRCT double-blind, randomised, placebo-controlled trial, XR extended release, mod moderate, # number, HFs hot flushes/flashes, VMS vasomotor symptoms, C greater than
or equal to, B less than or equal to,[ greater than,\ less than, mg/d milligrams/day, (m)ITT (modified) intention-to-treat, BL baseline, 1 primary, 2 secondary, avg.
average, D change, sig. significant, ns not significant, : increase, ; reduced, diff. difference, Tx treatment, (S)AEs (serious) adverse events, (S) or (D) BP (systolic) or (diastolic)
blood pressure, LFTs liver function tests, ALT alanine aminotransferase, AST aspartate aminotransferase, NASH non-alcoholic steatohepatitis, ULN upper limit of normal,
MENQoL Menopause-Specific Quality of Life questionnaire, HFRDIS Hot Flash-Related Daily Interference Scale, PEG The Pain Enjoyment of Life and General Activity scale,
PHQ-9 9-item Patient Health Questionnaire, GAD-7 7-item Generalized Anxiety Disorder questionnaire, PSS Perceived stress scale
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Table 5 Neurokinin 3 receptor antagonists (NK3Ra) study results





DBRCT; Cross-over trial: 1 UK centre
Mean age = 55 years (49–62)
Mean BMI = 25.85 kg/m2
38 randomised to 4 weeks MLE4901 (40 mg BID) and 4
weeks placebo (BID) in random order separated by a
2-week washout period
37 included in ITT analysis
1:
# of weekly HFs during week
2:
HF severity, bother and





; in weekly # of HFs from BL vs. placebo [ITT adjusted
means: 19.35 (73%;) vs. 49.01 (28%;], respectively;
p\ 0.001]
2:
; HF severity score from BL vs. placebo [3.27 (44%;) vs.
5.70 (5%;), p\ 0.0001], ; bother score (2.92 vs. 5.56,
p\ 0.0001), and ; interference score (7.94 vs. 26.48,
p\ 0.0001)
3 developed a transaminase rise (ALT 4.5–5.9 9 upper
limit of normal) but normal bilirubin, occurring 28 days
after starting, which normalised within 90 days






Prague et al. [30] reports a post hoc time course analysis of
Prague et al. [29] to define therapeutic profile of
MLE4901 by comparing the mean daily total of HFs at
day 3, and mean weekly total after weeks 1, 2, 3, and 4 of
both Tx periods, and also compared with week 2 of the
BL period
Post hoc analysis of questionnaire data (minimum n = 33,
maximum n = 35)
# of HFs
HF severity, bother and
interference
Impact on sleep via:
# of night-time HFs
Individual MENQoL items
Individual HFRDIS items
; # of HFs from BL vs. placebo by day 3 (72%; vs. 21%;;
p\ 0.0001), maintained through to week 4
HF severity, bother & interference continued to improve vs.
placebo. At day 3:
; HF severity from BL by 38% (vs. 7%;; p\ 0.0001),
which ; to - 44% by week 4 (vs. 5%;)
;HF bother from BL by 39% (vs. 5%;; p\ 0.0001), which
; to - 50% by week 4
;HF interference from BL by 61% (vs. 24%;; p = 0.0006),
which ; to - 70% by week 4
Impact of sleep:
; night-time HFs from BL vs. placebo at week 4 (78%; vs.
22%;; p\ 0.0001). Improvements rapid, significant by
day 3 vs. placebo (p\ 0.0001)
Improved MENQoL psychosocial and physical domains at
week 4. Authors suggested due to improved sleep since
‘difficulty sleeping’, ‘lethargy’ and ‘tiredness’ improved at
week 4 (p\ 0.0001, p = 0.00128, and p = 0.0002,
respectively), and ‘lethargy’ and ‘tiredness’ improved by
day 3 (p = 0.0474 and p = 0.0132, respectively),
whereas ‘muscle ache’ and ‘physical strength’ did not
improve
Improved ‘sleep’ and ‘concentration’, significant by day 3
vs. placebo (sleep: p = 0.001; concentration:









DBRCT: 8 Belgian centres
Mean age = 53.5 years (44–64)
Mean BMI = 25.8 kg/m2
87 randomised (1:1) to fezolinetant 90 mg BID or placebo
for 12 weeks
87 included in mITT analysis (inferred from Fig. 2A but
this is unclear)
1:
D from BL in mean daily
total VMS score
(composite of # and
severity) at week 12
2:
Important AEs/SAEs
Discontinuation due to AEs
1:
; mean daily total VMS score from BL vs. placebo at week
4, 8 and 12 [week 12: 2.7 (91%;) vs. 14.4 (44%;); all
comparisons p\ 0.001]
2:
: AEs considered Tx-related vs. placebo (30.2% vs. 25%),
most commonly GI disorders (23% vs. 9%)
: discontinuations due to AEs (2 (4.7%) vs. 0)
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Table 5 continued






DBRCT; Dose-ranging: 51 US centres
Mean age = 54.6 years (41–65)
Mean BMI = 28.4 kg/m2
356 randomised (1:1) to fezolinetant BID 15, 30, 60, or
90 mg, or fezolinetant QD 30, 60, or 120 mg or placebo
for 12 weeks
349 included in mITT analysis
1:
Mean D in # of mod/severe
HFs from BL at weeks 4
and 12
Mean D in mod/severe HF




Discontinuation due to AEs
1:
All doses ; # of mod/severe HFs from BL vs. placebo at
week 4 (ranging 62–81%; vs. 39%) and week 12 (ranging
74–87%; vs. 55%); all p B 0.024
All doses ; mod/severe HF severity from BL vs. placebo at
week 4 (ranging 29–54%; vs. 12%;; all p B 0.0322) and
60 mg BID, 90 mg BID, and 60 mg QD at week 12
ranging (52–53%; vs. 32%;; all p B 0.016)
2:
AEs similar across Tx groups, with no indication of a dose
effect. Most commonly nausea, diarrhoea, fatigue
2 severe (but not serious) AEs considered Tx-related (both
60 mg QD): 1 cholelithiasis, 1 drug-induced liver injury
(ALT [14.1xULN] and AST [9.5xULN] in a woman
with obesity and NASH)
9 had ALT or AST[ 3xULN, and 3 (60 mg BID, 90 mg
BID, and 60 mg QD) had ALT or AST[ 8xULN.
None had total bilirubin[ 2xULN ;no cases met
criteria for Hy’s law. ALT/AST levels rapidly returned to
BL values after discontinuation/trended toward
normalization while on drug






Santoro et al. [33] reports results of 2 endpoints from
VESTA [32]
% achieving 50%, 70% and
90% ; from BL in # of
mod/severe HFs
Responder analyses
: C 50% responder rate (all doses p\ 0.05). All doses
numerical : in 70% and 90% responder rates (with
magnitude and sig varying by dose and responder rate)
Shorter time to 50% ; in HFs vs. placebo (2.2–8.4 days vs.






DBRCT; multiple-ascending-dose study: 3 US centres
Mean age = 55 years
Mean BMI = 28.18 kg/m2
76 randomised (3:1) to NT-814 vs. placebo within each of
4 sequential dose cohorts; 50, 100, 150, and 300 mg/day
for 2 weeks
76 included in mITT analysis
Pre-specified exploratory
efficacy endpoints:
D from BL in daily # of
mod/severe HFs at week 2
D from BL in avg. daily HF
severity at week 2
D from BL in daily #. of
waking due to night sweats
Important AEs/SAEs
Discontinuation due to AEs
50 mg and 100 mg no significant ; in HF endpoints.
(With 50 mg vs. placebo, mean HF frequency actually
higher (p = 0.048) although median HF frequency no
difference)
; # of mod/severe HFs from BL vs. placebo [150 mg 84%;
(p\ 0.001), 300 mg 66%; (p = 0.022) vs. 37%;]
Doses C 150 mg improved symptoms early (within week 1
of Tx)
;HF severity vs. placebo with 150 mg [41%; vs. 13%;
(p\ 0.001)]; 300 mg no sig. difference
;waking due to night sweats vs. placebo [150 mg 81%;
(p\ 0.001), 300 mg 63%; (p = 0.031) vs. 32%;)].
AEs similar with placebo, 50 mg, 100 mg and 150 mg
groups (slightly higher in 300 mg group)
Most common: mild somnolence and headache
No discontinuation due to AEs
DBRCT double-blind, randomised, placebo-controlled trial, XR extended release, mod moderate, # number, HFs hot flushes/flashes, VMS vasomotor symptoms, C greater than
or equal to, B less than or equal to,[ greater than,\ less than, mg/d milligrams/day, (m)ITT (modified) intention-to-treat, BL baseline, 1 primary, 2 secondary, avg.
average, D change, sig. significant, ns not significant, : increase, ; reduced, diff. difference, Tx treatment, (S)AEs (serious) adverse events, (S) or (D) BP (systolic) or (diastolic)
blood pressure, LFTs liver function tests, ALT alanine aminotransferase, AST aspartate aminotransferase, NASH non-alcoholic steatohepatitis, ULN upper limit of normal,
MENQoL Menopause-Specific Quality of Life questionnaire, HFRDIS Hot Flash-Related Daily Interference Scale, PEG The Pain Enjoyment of Life and General Activity scale,
PHQ-9 9-item Patient Health Questionnaire, GAD-7 7-item Generalized Anxiety Disorder questionnaire, PSS Perceived stress scale
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FDA [36] advise using the following menopause
definition: 12 months spontaneous amenor-
rhea, or 6 months amenorrhea plus
FSH[40mIU/ml, or 6 weeks post-surgical
menopause. Two SNRI trials did not appear to
fulfil the FDA definition and thus could have
included perimenopausal women [20, 24]. All
NK3Ra trials fulfilled the FDA definition, apart
from Depypere et al. [31] who allowed amen-
orrhea C 3 months if FSH[40 IU/L and oestra-
diol\0.21 nmol/L (which usually indicates
premature ovarian insufficiency but oestrogen
levels can vary in early stages).
HF Frequency and Severity
The FDA [36] advise enrolling subjects with C 7
moderate-severe HFs/day (or C 50/week). All
trials fulfilled this except 2 SNRI trials [20, 27]
which only required C 14 HFs/week and not all
were moderate or severe. Joffe et al. [27] rea-
soned that by not requiring C 7 HFs/day (which
only occurs in 7–9%), they enrolled a more
generalisable population, many of whom do
seek HF treatment. However, mild HFs may be
less challenging to relieve and thus Joffe’s effi-
cacy data could be potentially exaggerated.
HF Stability
A stable HF pattern is needed to minimise the
risk of a spontaneous HF reduction being
attributed to a study drug. Most trials required a
consistent minimum or\50% change in pat-
tern over 1–2 baseline weeks. However, two
SNRI trials [20, 21] failed to assess baseline sta-
bility and hence their results are potentially
unreliable. One SNRI trial [23] and one NK3Ra
trial [32] required C 50 HFs over any 7 consec-
utive days during the 35-day screening period,
yet separately used the week prior to randomisa-
tion as the baseline comparator, potentially
underestimating baseline HF comparisons.
Baseline Characteristics
Treatment and control groups were generally
well balanced. However, Evans et al. [20]
reported higher alcohol consumption (a
potential HF trigger) in their SNRI group but
addressed this using sensitivity analysis. Among
NK3Ra trials, Trower et al. [34] reported that the
NT-814 50 mg group had a higher baseline HF
frequency, severity and night-time awakenings
which likely accounts for the unexpected
observation of 50 mg showing less reduction in
HFs compared to placebo.
Comorbidity
All trials recruited ‘healthy’ women. While
safety data for the use of SNRIs in complex
patients has been collected elsewhere, it will be
important to establish efficacy and safety of
NK3Ras in complex patients during phase 3 or
post-market registry settings.
Washout of Prior HF Treatment
To avoid potential confounding effects, the FDA
[36] advises different HRT washout periods
depending on administration route. However, a
washout was not specified in one SNRI trial [20],
and too short a washout was used for one SNRI
[27] and one NK3Ra trial [31], thus a spill-over
effect may have occurred.
Placebo Control
The inclusion of a placebo arm comparator was
validated after a marked reduction in HF fre-
quency was noted after placebo administration
in trials [SNRI range (across all 7 trials) 25–58%;
NKR3a range 28–55%]. One method to attenu-
ate a large placebo response may be to specify
increased HF bother or a similar lifestyle mea-
sure as an inclusion criterion. Pinkerton et al.
[25], for example, which had the lowest placebo
response at week 12, required a score of C 12 on
the Greene Climacteric Scale (a standard ques-
tionnaire assessing physical and psychological
menopausal symptoms) at study entry.
Power and Sample Size
All SNRI trials undertook a power calculation,
except Evans et al. [20] which may have been
underpowered as the reduction in HF frequency
of 1.4/day was not statistically significant
(p = 0.06), despite a statistically significant
reduction in patient-perceived severity score.
Initial NK3Ra trials lacked prior efficacy data to
estimate treatment effect but instead used
power calculations based on the ability to detect
a treatment effect double the
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anticipated * 25% placebo effect [29] or based
on previous HF diary trials [31]. Fraser et al. [32]
powered based on prior NK3Ra efficacy [31],
but, due to drop-out, failed to achieve the
planned 40 subjects in 7/8 groups which may
have affected 12-week HF severity evaluation (in
which only 3 groups showed a significant
reduction). Trower et al. [34] based sample size
on a previous pilot study suggesting 8 subjects
per group was adequate, but since the 150 mg
group achieved all primary endpoints, the fail-
ure of 300 mg to show a statistically significant
reduction in HF severity at week 12 may have
been due to being underpowered.
HF Recording
All but three trials used retrospective paper
diaries to assess HF frequency and severity.
However, errors in compliance are major sour-
ces of bias and backfilling is common [37].
Prospective time-stamped electronic diaries
may give superior timeliness and completion
versus paper diaries [37] and were used in three
trials [29, 31, 32]. Encouraging respondents to
report HFs as they occur (as in one NK3Ra trial
[29]), rather than at the end of the day/the fol-
lowing morning, also reduces recall bias.
Estimating Night Sweats
Use of the ‘number of night-time awakenings’
in SNRI [21–23] and NK3Ra trials [34] is prob-
lematic. Night-sweats may not produce full
awakenings and may be under-reported. Dis-
parity between subjective and objective report-
ing widens at night [38]. Thus, questionnaires
such as MENQoL, which evaluate sleep quality
[28, 30, 31, 33] may be useful since improved
scores in ‘concentration’, ‘difficulty sleeping’,
‘tiredness’ and ‘lethargy’ correlate with HF
therapeutic benefit and may more accurately
reflect the impact on participants’ lives.
Discontinuation
If patient drop-out is high, statistical power may
be lost. With SNRI trials, early discontinuation
due to AEs, often due to nausea, was common
(5–29%), especially during week 1. When treat-
ing depression, SNRIs are usually titrated over
1–2 months to reduce AEs [39]. It is surprising
that only four of seven SNRI trials
[20, 22, 25, 27] used titration and, even in those
trials that did, the titration was very rapid (over
1 week) [22, 27]. In NK3Ra trials, early discon-
tinuation due to AEs was uncommon (5–7%).
Since HFs can continue for 12 years [4], longer
trials with SNRIs and NK3Ras are warranted to
evaluate long-term efficacy and tolerability/
safety.
SNRI Tolerability and Safety
Most SNRI trials were short (B 12 weeks), apart
from two trials which extended to 26 and
52 weeks, albeit with high dropout rates
[23, 26]. Higher-dose SNRIs have been associ-
ated with treatment-emergent hypertension
(likely due to increased potentiation of nora-
drenergic neurotransmission). A significant or
numerical increase in blood pressure was
reported in three SNRI trials [21, 22, 27],
although none was powered to evaluate this
endpoint (Table 4). A 1-year CV safety study
among 2118 subjects with HFs [40] and pooled
data from[6000 subjects receiving desven-
lafaxine for various indications [21] did not
report a significant excess of CV events but
1 year may be too short; the Framingham Heart
Study showed an association
between * 10 mmHg increase in blood pressure
and increased CV events took 4–6 years to
emerge [41].
NK3Ra Tolerability and Safety
Since only short-duration phase 2 data have
been published, it was not possible to fully
evaluate NK3Ra tolerability and safety. In two
trials, participants taking NK3Ras reported a
higher frequency of minor GI disorders [31, 32],
which could be related to NK3R expression in
the GI tract [42]. However, the AE incidence did
not appear dose-dependent. Somnolence was
also more common (69% vs. 17%) with the
highest (300 mg) dose of NT-814 [34] likely due
to its additional NK1Ra action [43]. Interest-
ingly, this could be an advantage for women
with sleep disturbance. Asymptomatic rises in
transaminases[3 times the upper limit of nor-
mal were reported with MLE4901 [29] and
fezolinetant [32] but bilirubin did not rise[2
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times upper limit of normal. Liver function tests
(LFTs) returned to normal after drug discontin-
uation. However, further safety analyses are
required.
Potential Study Bias
Overall risk of bias was low (Table 3). Selection
bias was minimised by randomised study
designs. Unreported data leading to potential
reporting bias was noted, including pre-speci-
fied data on quality of life [21–23, 33], 50% HF
responder rates [21] and apparent differences in
gastrointestinal AE frequency in abstract versus
table [31]. Potential conflicts of interest were
considered under reporting bias but most trials
declared conflicts and often had industry co-
authors, which is common for these types of
studies. All trials were double-blind (except one
[20] using matched placebo) which should have
reduced performance bias and detection bias,
although this is difficult to fully exclude. One
SNRI trial included an HRT arm [24] in which
subjects experienced significant bleeding com-
pared with the desvenlafaxine or placebo
groups which likely unblinded treatment allo-
cation. High drop rates of[20% occurred in
several trials [20, 21, 23, 24, 26, 29] leading to
potential attrition bias [44], although this risk
was reduced by appropriate use of intention-to-
treat (ITT) or modified ITT rather than per-pro-
tocol analysis for primary outcomes.
Potential Additional Benefits of NK3Ra
Onset of Therapeutic Effect
Prague et al. [30] reported symptom improve-
ment after * 48 h with NK3Ras, with maxi-
mum effect by day 3. Thus, NK3Ras would be
expected to give earlier symptom relief versus
SNRIs, especially given the slow dose titration
recommended for SNRIs.
Sleep Quality/Concentration
Improved sleep ± concentration was noted in
three NK3Ra trials [30, 31, 34]. This is likely
attributed to multiple factors including reduced
sleep disruption from HFs, and the attenuation
of NK3R actions in melanin-concentrating
hormone neurons (involved in the sleep–wake
cycle) and in the prefrontal cortex, an impor-
tant area for concentration [45], whereas the
additional NK1Ra action of NT-814 may atten-
uate substance P-induced arousal and facilitate
sleep [43]. In contrast, SNRIs are non-sedating
[46], hence a reduction in night-time awaken-
ing with SNRIs is likely due to HF reduction and
anxiolysis.
Mood
SNRIs improve depressed mood (another com-
mon menopausal symptom). Although it is
unclear if NK3Ras directly affect mood, the
NK1Ra action of NT-814 may be of benefit [47].
In addition to pharmacotherapy, it may also be
worth considering cognitive behavioural ther-
apy (CBT) if mood is a particularly limiting
symptom, as the positive effects of CBT appear
to be sustained over time [48].
CV Safety
After menopause, CV risk increases. In contrast
to SNRIs which may be associated with hyper-
tension leading to increased CV risk (discussed
above), NK3Ras in rats reversed spontaneous
hypertension and lowered heart rate [49] via
reducing midbrain dopaminergic signalling in
the ventral tegmental area that highly expresses
NK3Rs [50]. Vasopressin neurones also express
NK3Rs [51], and NKB activity is potentiated by
thromboxane A2 [52] which might also repre-
sent useful therapeutic targets for NK3Ras.
Limitations of This Analysis
Conclusions of our qualitative analysis are lim-
ited by published data for NK3Ra being only
phase 2 trials. Longer duration phase 3 trials are
ongoing, and findings will provide further
insights into efficacy and safety outcomes [53].
Availability of phase 3 NK3Ra data would also
facilitate meta-analysis, enabling determination
of a weighted pooled estimate for HF reduction
in NK3Ra versus SNRI trials, although the ideal
trial to compare NK3Ras versus SNRIs for
reduction of menopausal HFs would be a large
phase 3 head-to-head trial.
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CONCLUSIONS
Menopausal HFs can significantly impact a
woman’s quality of life, but some women can-
not or do not wish to take HRT to alleviate their
symptoms. Current non-hormonal options are
suboptimal due to variable efficacy and low
tolerability. The recent discovery that NKB-
NK3R signalling is implicated in the generation
of menopausal HFs has led to recent clinical
trials using NK3Ras. Qualitative analysis of
these trials indicates that NK3Ras lead to greater
reductions in mean HF frequency, HF severity
and night-sweats with good short-term tolera-
bility compared to SNRIs. Efficacy and safety
data (including careful evaluation of LFTs) from
phase 3 trials are awaited with interest.
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